An IMF Myeloma Minute Special Report
US FDA Panel Backs Wider Use for Novartis' Zometa
ROCKVILLE, Md., Jan 31 (Reuters) - A U.S. advisory panel on Thursday backed a new use for Swiss health-care company Novartis AG's (NYSE:NVS - news) Zometa, a drug used to treat cancer complications.
The panel, which gives advice to the Food and Drug Administration, said it supports Zometa for treating bone metastases, the spread of cancer to the bone, in patients with a variety of solid tumors. The FDA usually follows its panels' advice.
To view the entire article, please click here.
Help Us Help Others...
As a non-profit organization, the IMF is completely dependent on the support of our members. Please consider showing your support by making a tax-deductible donation today. Donations in honor of a friend or family member make great gifts and are a wonderful way to celebrate a special occasion. You can donate online or by calling the IMF at (800) 452-CURE. We sincerely thank you for your support.
Tell A Friend...
The Myeloma Minute is a great way to stay abreast of the latest developments within the myeloma community. We hope you'll share this information with friends, family members and physicians and encourage them to sign up for their own copy by forwarding this message. New users can register by clicking here.
If you no longer wish to receive the Myeloma Minute, please visit the log-in page, enter your email address, password, first and last name and click the "unsubscribe" button at the bottom of the page.
View Back Issues Online...
New to the IMF Myeloma Minute? See what you've been missing by viewing previous issues online!